The effects of chromium and vitamin [D.sub.3] co-supplementation on insulin resistance and tumor necrosis factor-[alpha]lpha in type 2 diabetes: a randomized placebo-controlled trial

• Published in: Applied physiology, nutrition, and metabolism Vol. 45; no. 5; p. 471
• Main Authors: Imanparast, Fatemeh, Javaheri, Javad, Kamankesh, Fatemeh, Rafiei, Fatemeh, Salehi, Ashraf, Mollaaliakbari, Zeinab, Rezaei, Fatemeh, Rahimi, Abbas, Abbasi, Elnaz
• Format: Journal Article
• Language: English
• Published: NRC Research Press 01.05.2020
• Subjects: Analysis; Blood sugar; Clinical trials; Diabetes therapy; Diet therapy; Glycosylated hemoglobin; Insulin resistance; Necrosis; Tumor necrosis factor; Tumors; Type 2 diabetes; Vitamins; Iran
• ISSN: 1715-5312; 1715-5320
• DOI: 10.1139/apnm-2019-0113

The current study was conducted to assess the effects of simultaneous usage with vitamin [D.sub.3] and chromium picolinate (CrPic) supplementations on homeostasis model assessment of insulin resistance (HOMA-IR), fasting blood glucose (FBS), hemoglobin A1c (HbA1c), tumor necrosis factor-[alpha] (TNF-[alpha]), and lipid profile in type 2 diabetes mellitus (T2DM). Ninety-two patients with T2DM were randomly allocated to the following 4 groups for 4 months: (I) placebo of vitamin [D.sub.3] (n = 23); (II) vitamin [D.sub.3] supplement at a dose of 50 000 IU/week (n = 23); (III) CrPic supplement at a dose of 500 [micro]g/day (n = 23); and (IV) both vitamin [D.sub.3] at a dose of 50 000 IU/week and CrPic at a dose of 500 [micro]g/day (n = 23). HOMA-IR levels increased significantly in groups I and II after the intervention. However, this increase in group I was significantly higher than that in group II after the treatment. HOMA-IR levels were controlled in groups III and IV during the intervention. TNF-[alpha] decreased significantly in groups II, III, and IV after the intervention. FBS, HbA1c, and lipid profile did not change significantly in total groups after the intervention. It seems that chromium and vitamin [D.sub.3] co-supplementation are probably effective in controlling HOMA-IR by decreasing TNF-[alpha] in T2DM. Novelty * Chromium alone and/or in simultaneous pretreatment with vitamin [D.sub.3] is more effective than vitamin [D.sub.3] in controlling HOMA-IR in T2DM. * Chromium and vitamin [D.sub.3] alone and/or in simultaneous pretreatment decrease TNF-[alpha] in T2DM. Key words: type 2 diabetes mellitus, vitamin [D.sub.3], chromium picolinate, insulin resistance, inflammatory response, hemoglobin A1c. La presente etude vise a evaluer les effets de l'utilisation simultanee de supplements de vitamine [D.sub.3] et de picolinate de chrome (<< CrPic >>) sur l'insulinoresistance (homeostasis model assessment of insulin resistance (<< HOMA-IR >>)), la glycemie a jeun (<< FBS >>), l'hemoglobine A1c (<< HbA1c >>), le facteur de necrose tumorale alpha (<< TNF-[alpha] >>) et le profil lipidique chez des personnes aux prises avec le diabete de type 2 (<< T2DM >>). On repartit au hasard dans quatre groupes 92 patients aux prises avec le T2DM pour consommer per os pendant quatre mois: (I) un placebo de vitamine [D.sub.3] (n = 23), (II) un supplement de vitamine [D.sub.3] a raison d'une dose de 50 000 UI/semaine (n = 23), (III) un supplement de CrPic a raison d'une dose de 500 [micro]g/jour (n = 23) et (IV) un supplement de vitamine [D.sub.3] a raison d'une dose de 50 000 UI/semaine et de CrPic a raison d'une dose de 500 [micro]g/jour (n = 23), respectivement Apres l'intervention, les taux de HOMA-IR sont significativement plus eleves dans les groupes I et II. Cependant, apres l'intervention, le groupe I presente une augmentation significativement plus elevee que celle du groupe II. Les taux d'HOMA-IR sont controles pendant l'intervention dans les groupes III et IV. Le TNF-[alpha] diminue significativement dans les groupes II, III et IV apres l'intervention. FBS, HbA1c et le profil lipidique ne varient pas significativement dans l'ensemble des groupes apres l'intervention. Il semble que la supplementation en chrome et en vitamine [D.sub.3] soit probablement efficace pour controler HOMA-IR en diminuant le TNF-[alpha] chez les patients aux prises avec le T2DM. [Traduit par la Redaction] Les nouveautes * Le chrome seul et/ou en pretraitement simultane avec la vitamine [D.sub.3] est plus efficace que la vitamine [D.sub.3] dans le controle de l'HOMA-IR dans le T2DM. * Le chrome et la vitamine [D.sub.3] seuls et/ou simultanement au pretraitement diminuent le TNF-[alpha] dans le T2DM. Mots-cles : diabete de type 2, vitamine [D.sub.3], picolinate de chrome, insulinoresistance, reponse inflammatoire, hemoglobine A1c.